The role of beta-tubulin isotypes in resistance to antimitotic drugs.
about
HP1 recruits activity-dependent neuroprotective protein to H3K9me3 marked pericentromeric heterochromatin for silencing of major satellite repeatsA ubiquitous beta-tubulin disrupts microtubule assembly and inhibits cell proliferationDrug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics.Targeting β-tubulin:CCT-β complexes incurs Hsp90- and VCP-related protein degradation and induces ER stress-associated apoptosis by triggering capacitative Ca2+ entry, mitochondrial perturbation and caspase overactivation.VDAC inhibition by tubulin and its physiological implications.Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancerMechanisms of Taxol resistance related to microtubules.Docetaxel-carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer.Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer.RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cellsMicroRNAs: key players of taxane resistance and their therapeutic potential in human cancers.Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy.Second generation benzofuranone ring substituted noscapine analogs: synthesis and biological evaluationEndometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agentsPhase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada Clinical Trials GroupCombined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapyExpression of ERCC1 and class III β-tubulin is associated with the survival of resected stage III non-small cell lung cancer patients treated with induction chemoradiotherapy using carboplatin-taxane.Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study.Altered TUBB3 expression contributes to the epothilone response of mitotic cells.The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers.The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells.Modulation of the anti-cancer efficacy of microtubule-targeting agents by cellular growth conditions.A label-free mass spectrometry method for the quantification of protein isotypes.Molecular basis for class V beta-tubulin effects on microtubule assembly and paclitaxel resistance.Collagen gel droplet-embedded culture-drug sensitivity test and Ki67 expression in estrogen receptor-positive and HER2-negative breast cancer.Modelling the microtubule: towards a better understanding of short-chain fatty acid molecular pharmacology.The role of Tau protein in resistance to paclitaxel.Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.Biology-oriented synthesis of a tetrahydroisoquinoline-based compound collection targeting microtubule polymerization.Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.Taxotere resistance in SUIT Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines.Human mutations that confer paclitaxel resistance.EGFR and K-RAS mutations and ERCC1, TUBB3, TYMS, RRM1 and EGFR mRNA expression in non-small cell lung cancer: Correlation with clinical response to gefitinib or chemotherapy.High expression of class III β-tubulin in small cell lung carcinoma.Prognostic significance of the mRNA expression of ERCC1, RRM1, TUBB3 and TYMS genes in patients with non-small cell lung cancer.Analysis of Beta-Tubulin Gene Exon 4 Mutations in Advanced Stage III or IV Gastric Cancer.The roles of beta-tubulin mutations and isotype expression in acquired drug resistance.
P2860
Q28476760-9B5F95C3-901A-4ECD-8E4C-65D252C89CCFQ28512163-C4264729-7BA4-4729-9BBC-63FD85592B96Q30438642-1B3321A2-BFB8-4077-A478-01F34451FB67Q30532061-4077C61F-2A5F-45BF-A013-BFA2DA16E139Q33352565-33F58836-C19D-4D19-9129-5BBE98080EFDQ33589802-9C9014C2-4EEB-4E83-A394-EE4D185B36AAQ33688044-FEA91C6C-27A8-4871-ABC7-F966D5E07E13Q33819310-E36BFFC8-ED13-46DA-92B5-DB025A00A259Q33903541-0301E9C7-A3D7-4596-BC75-1AEE55DB2A0AQ33918055-B7B3C626-D795-42CD-94F0-3475AEDFB1ECQ34048144-CA6C6DF7-463A-455D-8D5F-C00F132C3337Q34048154-0E0C8C44-5017-4FFD-8ED0-0A7D36C3F10CQ34154782-BF33BD7C-8A70-4A74-8E8B-326E02F4825EQ34428153-94AF6C8C-AB35-460E-9DE4-1C218F67AE41Q35231775-6B53B1F9-985B-42F7-B95B-96E95E01394CQ35583750-D5F9C7EF-24DB-4E11-847B-A30E06A00E36Q35800455-F70A52CF-D845-4423-A747-4AB8493F01CFQ35916938-BEE59F9D-1CD0-441C-92CC-0FAB98DF11DBQ36244183-B5216C4F-6438-4458-9B75-8FF6F10F1756Q36411072-35BD4186-33F0-43D2-A2B6-65BBF2101CD7Q36502964-1E36CA61-116D-446E-98AC-8B5F5BD7F604Q36557893-E8A51F4B-DF4D-418C-83BA-21A2FB3BADA5Q36610771-52ED3EF7-28B4-4D71-BCB4-D139BCC296DCQ36679410-8AEBA135-528F-47F4-A6D6-A85C86FCF3F1Q36753454-25F83FA9-518E-4937-AD5D-C1871C931BF5Q37013235-3DE025C4-1A42-4C81-8B4D-34A299FE710CQ37176441-539D3E43-3473-4D03-ABC9-5CAC8C1602A2Q37641078-3DBD68CF-D26B-45B8-B60C-7900D53C70C8Q37833936-7E49B7DB-F655-4D03-BBE4-DE454E2EF806Q37895519-8114E1B6-1638-4ACB-B886-FFF082BF1569Q38695528-C8A3C687-68B0-44A4-BD3A-E82F4A1C3F25Q39201808-EE47E0C2-887C-4E24-9089-E076C6515A04Q39636515-EB0024A6-B196-45BD-B0E6-D93704295598Q40749621-0E18AB09-01F4-427B-B8A2-DA3FFE16132FQ41769659-6C892160-78F6-4144-ACC6-428C43FF0F36Q41829016-5ED3DF60-6E07-4C1B-B30B-0475C018291EQ41852975-1AFB5B81-0D5D-49AE-B9C9-F08149ABF03FQ42069551-2FD85B5E-6EF5-41FD-A999-FEEAD7924776Q43088504-921730A8-4A5A-4146-8057-A23E03C9ECB7Q43137052-44D78B11-5CE5-4A11-B1E1-70A8B00F8BF2
P2860
The role of beta-tubulin isotypes in resistance to antimitotic drugs.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The role of beta-tubulin isotypes in resistance to antimitotic drugs.
@ast
The role of beta-tubulin isotypes in resistance to antimitotic drugs.
@en
The role of beta-tubulin isotypes in resistance to antimitotic drugs.
@nl
type
label
The role of beta-tubulin isotypes in resistance to antimitotic drugs.
@ast
The role of beta-tubulin isotypes in resistance to antimitotic drugs.
@en
The role of beta-tubulin isotypes in resistance to antimitotic drugs.
@nl
prefLabel
The role of beta-tubulin isotypes in resistance to antimitotic drugs.
@ast
The role of beta-tubulin isotypes in resistance to antimitotic drugs.
@en
The role of beta-tubulin isotypes in resistance to antimitotic drugs.
@nl
P2093
P1476
The role of beta-tubulin isotypes in resistance to antimitotic drugs.
@en
P2093
C A Burkhart
M Kavallaris
S Band Horwitz
P356
10.1016/S0304-419X(00)00022-6
P407
P577
2001-01-01T00:00:00Z